# Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Source: https://onco.cc/trials/nsclc-2/  
OnCo record `nsclc-2` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial testing Budigalimab in non-small-cell lung cancer, active and no longer recruiting.

## Summary

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) is a phase 2/3 interventional study registered as NCT06236438, led by AbbVie, and active but no longer recruiting on the registry. Official title: A Randomised, Phase 2/3 Study to Evaluate the Optimal Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC). Planned enrolment is 840 participants (estimated). The study started in 2024-04-10 and primary completion is expected in 2031-10. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-10-19
- Also known as: LIVIGNO-4
- Tags: ctgov-ingest
- Registry id: NCT06236438
- Phase: 2/3
- Setting: A Randomized, Phase 2/3 Study to Evaluate the Optimal Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Sponsor: AbbVie
- Enrolled: 840

## Notes

- Registry status on 19 October 2026: Active, not recruiting (registry record last updated 19 October 2026; primary completion expected October 2031).

## Sources

- ClinicalTrials.gov NCT06236438: https://clinicaltrials.gov/study/NCT06236438

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Budigalimab](https://onco.cc/drugs/budigalimab/), [Livmoniplimab](https://onco.cc/drugs/livmoniplimab/)
- companies: [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/)

---
JSON: https://onco.cc/api/v1/entities/nsclc-2.json